Novartis expands HCV plans with Enanta collaboration; $34M upfront in $406M deal
This article was originally published in Scrip
Executive Summary
Private biotechnology firm Enanta Pharmaceuticals Inc. continued a five-year streak of funding its operations through strategic partnerships by executing an exclusive collaboration and license agreement worth up to $406 million with Novartis for its once-daily small molecule candidate EDP-239 to treat hepatitis C virus (HCV) infections.